TTrialPathMatch Me to Trials
← Back to trials
RecruitingColorectal Cancer PreventionColorectal Adenoma

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

Eligible age

18–50 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial approach for a future larger study.

Sponsor: Massachusetts General Hospital

You may qualify if…

  • ✓ Age 18-50 years Because no dosing or adverse event data are currently available on the use of tirzepatide in participants \<18 years of age, children are excluded from this study. Because we are specifically studying the prevention of EOCRC, which is defined as CRC occurring prior to age 50, the study population will only enroll participants under the age of 50 at baseline.
  • ✓ BMI between 27 and 40 kg/m2
  • ✓ Underwent a screening or surveillance colonoscopy within the prior 9 months.
  • ✓ Removal of multiple (at least 2) colon or rectal adenomas (including sessile serrated adenomas but excluding hyperplastic polyps) or a single adenoma ≥6mm in size during the last colonoscopy
  • ✓ Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

  • ✕ Participants who have ever taken incretin mimetic therapies.
  • ✕ Participants with a history of medullary thyroid cancer or MEN 2 syndrome.
  • ✕ Participants at high risk of pancreatitis or otherwise contraindicated for use of tirzepatide according to clinical labeling.
  • ✕ Participants with a history of cancer (excluding non-melanoma skin) within the last three years
  • ✕ Participants with a history of diabetes mellitus
  • ✕ Participants with a history of bowel surgery
  • ✕ Participants with hereditary cancer syndromes, including HNPCC/Lynch syndrome or familial adenomatous polyposis
  • ✕ Participants with a history of inflammatory bowel disease, Crohn's, or colitis.

Where it's recruiting

Massachusetts

Boston

Source: ClinicalTrials.gov · NCT07095517 · last updated 2026-02-27

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorecta · TrialPath